Document:

Exhibit 10.29

 

Addendum
Number 4 to the

Convertible Loan Agreement

 

 

“Addendum”

 

of

 

January 8, 2021

 

between

 

NLS Pharmaceutics
AG

Alter Postplatz 2

6370 Stans

Switzerland

“Borrower”

 

and

 

	Alexander Zwyer	 
	  

	 
	 	 
	Switzerland	“Lender”

 

 

(Borrower and Lender
each a “Party”

collectively the “Parties”)

 

 

regarding

extension of maturity date

 

     

    	Addendum	2/3

    

 

WHEREAS 

 

		A.	The Borrower is a stock corporation (Aktiengesellschaft) in accordance with Swiss law with
its registered seat and principal place of business at Stans (company number CHE-447.067.367). The Company has a share capital
of CHF 139’200.00, divided into 6’960’000 registered shares with a nominal value of CHF 0.02 each, which
have been fully paid in.

 

		B.	The Lender and the Borrower entered into a convertible loan agreement dated 21 February 2020, as
amended on 15 September 2020 (“Agreement”). The Lender agreed to make available to the Borrower a convertible
loan in the amount of CHF 150’000 (“Loan Amount”). This Loan Amount was reduced with the amendment dated
15 September 2020 to CHF 100’000.00 (“New Amount”). The Lender granted to the Borrower the New Amount.

 

		C.	The Maturity Date for the repayment of the Convertible Loan together with accrued interest was
set at 31 December 2020 (“Maturity Date”).

 

NOW,
THEREFORE, the Parties agree as follows:

 

Any capitalized terms, if not defined otherwise
in this Addendum, shall have the meaning as set forth in the Agreement.

 

		1.	Open Amount

 

The Parties hereby
confirm that the Convertible Loan has not been repaid to the Lender by the Borrower. 

 

		2.	Extension of Maturity Date

 

The Maturity Date as set forth
in section 4 of the Agreement shall be extended from 31 December 2020 to 31 March 2021.

 

The Parties therefore confirm
that no default interest as set forth in section 2.2 of the Agreement has accrued so far. In any case, the Lender waives any claim
with regard to regular and default interest.

 

		3.	Governing Law and Jurisdiction

 

This Addendum shall be governed
by and construed in accordance with the substantive laws of Switzerland, without reference to principles of conflict of laws or
choice of laws.

 

All disputes arising out of
or in connection with the Addendum, including disputes on its conclusion, binding effect, amendment and termination, shall be resolved
by the ordinary courts in Stans (NW), Switzerland.

 

 

[signature page to follow]

 

     

    	Addendum	3/3

    

 

Borrower

 

NLS Pharmaceutics AG

 

	/s/ Alexander Zwyer	 	/s/ Ronald Hafner
	
        Name: Alexander Zwyer
	 	
        Name: Ronald Hafner

	
        Function: Chief Executive Officer
	 	
        Function: Chairman of the Board

 

 

Lender

 

	/s/ Alexander Zwyer	 
	Alexander ZwyerExhibit 10.30

 

2nd
Amendment to the

Series A Loan Agreement

 

 

“Amendment”

 

 

of

 

 

 

 

 

between

 

 

NLS
Pharmaceutics AG

Alter
Postplatz 2

CH-6370
Stans

“Borrower”

 

 

and

 

 

Magnetic
Rock Investment AG

c/o
Ronald Hafner

 

 

 

“Lender”

 

 

(Borrower
and Lender each a “Party”

collectively
the “Parties”)

 

     

    	Amendment
	2/3

    

 

WHEREAS

 

		A.	The
                                         Borrower is a Swiss stock corporation with its registered office at Alter Postplatz 2,
                                         6370 Stans, Switzerland, and company no. CHE-447.067.36 active in the area of developing
                                         and commercializing the active ingredient Mazindol for the treatment of ADHD.

 

		B.	The
                                         Lender and the Borrower entered into a duly executed series A loan agreement, as amended
                                         in October 2020 (“Agreement”), whereas the Lender grants to the Borrower
                                         a loan in the amount of CHF 500’000.00 (“Loan Amount”).

 

		C.	The
                                         maturity date for the repayment of the Loan Amount with accrued interest was set at 31 December
                                         2020 (“Maturity Date”).

 

NOW,
THEREFORE, the Parties agree as follows:

 

Any
capitalized terms, if not defined otherwise in this Amendment, shall have the meaning as set forth in the Agreement.

 

		1.	Extension
                                         of Maturity Date

 

The
Maturity Date as set forth in section 6 of the Agreement shall be retrospectively extended from 31 December 2020 to 31 March 2021.

 

The
Parties therefore confirm that no default interest as set forth in section 4.2 of the Agreement has accrued so far. In any case,
the Lender waives any claim with regard to default interest.

 

		2.	Governing
                                         law and jurisdiction

 

		2.1.	Governing
                                         Law

 

This
Amendment shall in all respects be governed by and construed in accordance with the substantive laws of Swiss law.

 

		2.2.	Jurisdiction

 

All
disputes arising out of or in connection with this Amendment, including disputes regarding its conclusion, validity, binding effect,
amendment, breach, termination or rescission shall be subject to the exclusive jurisdiction of the ordinary courts of Zurich,
canton of Zurich, Switzerland, venue being Zurich 1.

 

 

[signature
page to follow]

 

     

    	Amendment
	3/3

    

 

IN
WITNESS WHEREOF, the Parties have signed this Amendment on the date first written above

 

Magnetic
Rock Investment AG

 

	/s/
    Ronal Hafner	 	 
	Name: Ronald Hafner	 	Name:
	Function: Chairman of the Board	 	Function: 
	 	 	 
	 	 	 
	NLS
    Pharmaceutics AG	 	 
	 	 	 
	/s/ Alexander
    Zwyer	 	/s/ Ronald Hafner
	Name: Alexander Zwyer	 	Name: Ronald Hafner
	Function: Chairman
    of the Board	 	Function: Chairman
    of the BoardExhibit 10.31

 

3rd
Amendment to the

Series A Loan Agreement

 

 

“Amendment”

 

 

of

 

 

 

 

 

between

 

 

NLS Pharmaceutics AG

Alter Postplatz 2

CH-6370 Stans

“Borrower”

 

 

and

 

 

Magnetic Rock Investment
AG

c/o Ronald Hafner

Weinbergstrasse 72

CH-8703 Erlenbach
ZH 

“Lender”

 

 

(Borrower and Lender each
a “Party”

collectively the “Parties”)

 

     

    	Amendment
	2/3

    

 

WHEREAS

 

		A.	The Borrower is a Swiss stock corporation with its registered office at Alter Postplatz 2, 6370
Stans, Switzerland, and company no. CHE-447.067.36 active in the area of developing and commercializing the active ingredient Mazindol
for the treatment of ADHD.

 

		B.	The Lender and the Borrower entered into a duly executed series A loan agreement, as amended in
October 2020 and on 8 January 2021 (“Agreement”), whereas the Lender granted to the Borrower a loan in the amount
of CHF 500’000 (“Loan Amount”).

 

		C.	The Lender intends to grant the Borrower an additional loan by increasing the Loan Amount from
CHF 500’000 to CHF 600’000.

 

NOW,
THEREFORE, the Parties agree as follows:

 

Any capitalized terms, if not defined otherwise
in this Amendment, shall have the meaning as set forth in this Agreement.

 

		1.	Increase of Loan Amount

 

The Parties herewith confirm,
that the first tranche of CHF 300’000 and the second tranche of CHF 200’000 as per section 2 of the Agreement have been paid out
from the Lender to the Borrower and are, as per this date, still outstanding (including accrued interest).

 

The Loan Amount as set forth
in section 2 of the Agreement shall be increased from CHF 500’000 to CHF 600’000. The additional loan of CHF 100’000 shall constitute
the third tranche of the Loan (“Third Tranche”). The term “Loan” as used in the Agreement and in the Amendment
shall include the Third Tranche, and all provisions of the Agreement shall mutatis mutandis apply to the Third Tranche, unless
provided otherwise in this Amendment.

 

The Third Tranche shall become
payable within 2 Business Days after the execution of this Amendment and transferred to an account designated by the Borrower.

 

Interest on the Third Tranche
shall be calculated from (and including) the date of receipt of the Third Tranche on the bank account as designated by the Borrower
to (and including) the Maturity Date. On 8 January 2021, the maturity date for the repayment of the Loan Amount with accrued interest
was extended from 31 December 2020 to 31 March 2021. For the avoidance of doubt, the Third Tranche (including accrued and unpaid
interest) shall become due for repayment on the Maturity Date (i.e. 31 March 2021).

 

		2.	Governing law and jurisdiction

 

		2.1.	Governing Law

 

This Amendment shall in all
respects be governed by and construed in accordance with the substantive laws of Switzerland.

 

		2.2.	Jurisdiction

 

All disputes arising out of
or in connection with this Amendment, including disputes regarding its conclusion, validity, binding effect, amendment, breach,
termination or rescission shall be subject to the exclusive jurisdiction of the ordinary courts of Zurich, canton of Zurich, Switzerland,
venue being Zurich 1.

 

 

[signature page to follow]

 

     

    	Amendment
	3/3

    

 

IN WITNESS WHEREOF, the Parties
have signed this Agreement on the date first written above

 

Magnetic Rock Investment AG

 

	/s/ Ronald Hafner	 	 
	Name: Ronald Hafner	 	Name:
	Function: Chairman of the Board	 	Function:
	 	 	 
	 	 	 
	NLS Pharmaceutics AG	 	 
	 	 	 
	/s/ Alexander Zwyer	 	/s/ Ronald Hafner
	Name: Alexander Zwyer	 	Name: Ronald Hafner
	Function: Chairman of the Board	 	Function: Chairman of the BoardExhibit 10.32

 

NLS Pharmaceutics Ltd.

Alter Postplatz 2

CH-6370 Stans

 

___
January 2021

 

Addendum
Number 4 to Promissory Note (“Addendum”)

 

________,
_______ (the “Lender”), granted to NLS Pharmaceutics Ltd. (formerly NLS-1 Pharma AG), a Swiss stock
corporation with its registered office at Alter Postplatz 2, 6370 Stans, Switzerland, and company no. CHE-447.067.367 (the “Borrower”),
based on the promissory note, as amended on __ September 2019, __ February 2020 and in October 2020 (the “Promissory
Note”) the principal sum of CHF 125,000.00 (the “Principal Amount”), together with interest
at 10.0% p.a. (the “Interest”) thereon accruing on and from the date of payment until the entire Principal
Amount is repaid (the Interest and the Principal Amount hereinafter jointly referred to as the “Loan”).

 

The
Principle Amount was paid to the Borrower on _ January 2019 (the “Date of Payment”). The full amount of the
Loan, including accrued Interest, is outstanding as of the date of this Addendum.

 

The
following is a statement of the amended terms and conditions of the Promissory Note:

 

	1
        – Extension Maturity Date

         
	 	According
        to section 2 of the Promissory Note, the Loan shall be repaid in full on the Maturity Date and therefore the repayment
        of the Loan was agreed to take place no later than 31 December 2020.

         

        According
        to section 2 of the Promissory Note, the Lender may unilaterally extend the repayment term and set a new Maturity Date.

         

        The
Lender hereby extends the maturity date of the Loan, replacing the existing Maturity Date, until 31 March 2021 and, thus, the
Loan shall be due for repayment no later than 31 March 2021. The Borrower hereby acknowledges and agrees with the extension. References
to the Maturity Date in the Promissory Note shall be to 31 March 2021.

	 	 	 
	2
    - Governing Law	 	This
Addendum shall be governed by and construed in accordance with the substantive laws of Switzerland, without reference to principles
of conflict of laws or choice of laws. 

	 	 	 
	3
    – Jurisdiction	 	All
disputes arising out of or in connection with this Addendum, including disputes regarding its conclusion, validity, binding effect,
amendment, breach, termination or rescission shall be subject to the exclusive jurisdiction of the ordinary courts of Stans (NW).

 

     1

     

    

 

	The Lender	 	The Borrower	 	 
	 	 	NLS Pharmaceutics
                    Ltd.

	 
	 	 	 	 	 
	 	 	 	 	 
	[_____]

	 	Alexander Zwyer

	 	Ronald Hafner

		 	Chief Executive Officer

	 	Chairman of the Board
        of Directors

 

     2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]